AI screening for diabetic eye disease and macular degeneration
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 or older and being checked for age-related macular degeneration
- You have diabetes and are 20 or older, being checked for diabetic retinopathy
- You are visiting a non-retinal eye clinic (a general eye doctor, not a retina specialist)
- You agree to join the trial and can provide your permission
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
This study uses an artificial intelligence (AI) tool to analyze eye images in people with type 2 diabetes. The goal is to see if the AI can help detect early signs of diabetic eye disease, so you can get the right care sooner.
This study uses an AI program called DRISTi to screen for diabetic eye disease by taking pictures of the back of your eye. It's designed for adults with diabetes who haven't had major eye treatments or vision loss.
This trial is testing an automated tool that helps screen for diabetic retinopathy, a complication of diabetes that affects the eyes. The goal is to see if the tool can accurately detect the condition, which may help with early treatment and prevent vision loss.
This trial tests an AI system designed to catch early signs of late age-related macular degeneration (AMD) before it's diagnosed. It's for people who haven't yet been diagnosed with AMD or treated for retinal disease.
This study tests an AI platform that checks for diabetic retinopathy, a common eye problem in people with diabetes. It aims to see if the AI can spot signs of damage early, so you can get treatment sooner.
Hear when a new Age-Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.